Number of Clinical Trials 2012

Explore the number of clinical trials conducted in various countries; critical for medical research and innovation.

121 data pointsโ€ขโ€ขGlobal Coverageโ€ขNumber of clinical trials | ClinicalTrials.gov via Our World in Dataโ€ข

Newer data is available: Number of Clinical Trials by country 2024 โ†’

Highest
United States
4,887
Lowest
Mozambique
1
Median country
6
Countries with data
121

Where does your country rank? Pick it to see its position.

Related Health statistics

More โ†“

Interactive Map

Loading interactive map...

Complete Data Rankings

โ†‘Top 10 Countries

  1. #1United States flagUnited States
  2. #2France flagFrance
  3. #3Germany flagGermany
  4. #4Canada flagCanada
  5. #5South Korea flagSouth Korea
  6. #6United Kingdom flagUnited Kingdom
  7. #7China flagChina
  8. #8Brazil flagBrazil
  9. #9Italy flagItaly
  10. #10Japan flagJapan

Analysis: These countries represent the highest values in this dataset, showcasing significant scale and impact on global statistics.

โ†“Bottom 10 Countries

  1. #121Mozambique flagMozambique
  2. #120Madagascar flagMadagascar
  3. #119Lithuania flagLithuania
  4. #118Lesotho flagLesotho
  5. #117Kuwait flagKuwait
  6. #116Kazakhstan flagKazakhstan
  7. #115Iceland flagIceland
  8. #114Honduras flagHonduras
  9. #113Guinea-Bissau flagGuinea-Bissau
  10. #112Guadeloupe flagGuadeloupe

Context: These countries or territories have the lowest values, often due to geographic size, administrative status, or specific characteristics.

Insights by country

1

France

In 2012, France ranked #2 globally with a total of 511 clinical trials. This figure is notable as it reflects France's strong position in the European biomedical research landscape, where it often competes closely with Germany. Key factors contributing to this high number include France's robust healthcare system, significant investment in research and development, and a favorable regulatory environment that encourages clinical innovation.

2

Ghana

In 2012, Ghana ranked #62 globally with a total of 5 clinical trials. This number is relatively low compared to leading countries like the United States, which hosts thousands of clinical trials annually. Contributing factors to Ghana's position include its developing healthcare infrastructure and limited funding for research initiatives, which can hinder the growth of clinical research activities.

3

Colombia

In 2012, Colombia ranked #41 globally with a total of 18 clinical trials. This figure is notably lower than the leading countries in clinical research, reflecting the challenges faced in attracting investment in this sector. Factors such as a developing healthcare infrastructure, regulatory environment, and the need for enhanced research capabilities contribute to this landscape in Colombia.

4

Ecuador

Ecuador ranked #72 globally with a total of 3 clinical trials in 2012. This number is significantly lower than many countries in the region, reflecting the challenges faced in attracting research investment compared to its neighbors. Factors such as limited infrastructure for clinical research, a smaller healthcare market, and regulatory hurdles contribute to this low figure, impacting the country's ability to participate in global clinical research initiatives.

5

Burundi

In 2012, Burundi ranked #104 globally with a total of 1 clinical trial. This figure is notably low compared to many neighboring countries, indicating limited research activity in the region. Contributing factors include Burundi's economic challenges, a lack of infrastructure, and ongoing political instability, which hinder the development of a robust clinical research environment.

6

Russia

In 2012, Russia ranked #31 globally with 40 clinical trials conducted. This figure is notably lower than the global leader in clinical trials, the United States, which reflects the challenges faced in the Russian healthcare system. Contributing factors include regulatory hurdles, limited funding for research, and a need for greater international collaboration in clinical research initiatives.

7

Afghanistan

In 2012, Afghanistan ranked #101 globally with a total of 1 clinical trial. This figure is notably low compared to many neighboring countries, reflecting a significant gap in research and development capabilities in the region. The limited number of clinical trials can be attributed to ongoing conflict, inadequate healthcare infrastructure, and a lack of investment in scientific research. These factors hinder the country's ability to attract international pharmaceutical companies and research institutions.

8

Argentina

Argentina ranked #39 globally with 19 clinical trials in 2012. This number is relatively low compared to regional leaders like Brazil, which has a significantly higher count of trials. The country's clinical trial landscape is influenced by its robust pharmaceutical sector and a growing emphasis on research and development, supported by a diverse population that provides a wide range of clinical study participants.

9

China

In 2012, China ranked #7 globally with a total of 297 clinical trials. This figure reflects China's significant investment in medical research, surpassing many neighboring countries in the Asia-Pacific region. Contributing factors include a large population that provides diverse patient demographics and government policies aimed at enhancing the pharmaceutical industry and attracting foreign investment.

10

Greece

In 2012, Greece ranked #29 globally with a total of 42 clinical trials. This figure is notable compared to the top-ranked United States, which leads with thousands of trials, highlighting Greece's relatively modest position in the global clinical research landscape. Factors contributing to Greece's clinical trial activity include its strategic geographic location for European and Middle Eastern studies and a growing emphasis on improving healthcare infrastructure and research capabilities.

Analysis & Context

In 2012, the United States led the world in the Number of Clinical Trials, conducting a total of 4,887 studies. Globally, the number of clinical trials varied significantly, ranging from a minimum of 1 to the maximum achieved by the United States. The average number of clinical trials across 121 countries was 89.72, while the median stood at 6, highlighting a skewed distribution with a few countries conducting the majority of trials.

Concentration of Clinical Trials in Developed Nations

The data reveals a pronounced concentration of clinical trials in developed countries. The United States alone accounted for a substantial portion of global trials, with 4,887 trials, followed by France (511) and Germany (504). These countries, along with others like Canada (470) and the United Kingdom (344), benefit from advanced healthcare infrastructure, substantial funding, and established pharmaceutical industries. The high number of trials in these nations reflects their role as hubs of medical research and innovation.

In contrast, many developing countries recorded minimal clinical trial activity. For instance, countries such as Cambodia, Lesotho, and Madagascar each reported only 1 trial. The limited number of trials in these regions can be attributed to factors such as insufficient healthcare infrastructure, lower levels of investment in research, and regulatory challenges.

Economic and Policy Drivers

Economic factors and government policies significantly influence the distribution of clinical trials. Developed economies like the United States and Germany have the resources to support extensive research and development activities. Moreover, these countries often have policies that encourage pharmaceutical innovation, including tax incentives and streamlined regulatory processes.

In contrast, countries with fewer trials often face economic constraints that limit their ability to fund and conduct research. For example, Afghanistan and Chad, each with only 1 trial, may lack the necessary financial and institutional support to sustain large-scale clinical research. Efforts to increase clinical trial numbers in these regions often require international collaboration and investment.

Year-over-Year Trends and Their Implications

Examining the year-over-year changes, several countries experienced notable increases in the number of clinical trials. The United States saw an increase of 285 trials, representing a 6.2% growth. This growth can be linked to the countryโ€™s robust research ecosystem and ongoing investment in healthcare innovation. Similarly, Brazil added 63 trials, marking a 33.9% increase, indicative of its growing role in the global pharmaceutical industry.

Conversely, some countries saw a decrease in their trial numbers. Sweden experienced a reduction of 13 trials, a decline of 9.9%. Cuba saw one of the most significant percentage decreases at -88.9%, losing 8 trials. These declines may be due to shifts in research priorities, budget reallocations, or changes in regulatory environments that impact the feasibility and attractiveness of conducting trials in these regions.

The Role of Global Collaboration

Global collaboration plays a crucial role in the distribution of clinical trials. Countries like South Korea (382 trials) and Japan (234 trials) demonstrate how strategic partnerships and international collaborations can enhance their research capabilities. These nations often collaborate with Western pharmaceutical companies to conduct multi-center trials, leveraging their advanced healthcare systems and scientific expertise.

Such collaborations not only increase the number of trials conducted but also enhance the quality and diversity of research, contributing to global health advancements. Encouraging more international partnerships can help distribute clinical trials more evenly across different regions, providing broader access to new treatments and innovations.

In conclusion, the Number of Clinical Trials in 2012 underscores significant disparities between developed and developing nations, driven by factors such as economic resources, policy frameworks, and international collaborations. Understanding these dynamics is essential for stakeholders aiming to optimize global health research and ensure equitable access to medical advancements.

Frequently Asked Questions About Number of Clinical Trials in 2012

Which country had the highest number of clinical trials in 2012?

The United States had the highest number of clinical trials in 2012, with a total of 4,887 trials.

Which country had the lowest number of clinical trials in 2012?

Cambodia had the lowest number of clinical trials in 2012, with only 1 trial conducted.

What was the average number of clinical trials conducted per country in 2012?

The average number of clinical trials conducted per country in 2012 was 89.72.

What was the median number of clinical trials conducted by countries in 2012?

The median number of clinical trials conducted by countries in 2012 was 6.

How many countries were included in the dataset for clinical trials in 2012?

The dataset for clinical trials in 2012 included 121 countries.

Which countries were in the top 3 for the number of clinical trials conducted in 2012?

The top 3 countries for the number of clinical trials conducted in 2012 were the United States with 4,887 trials, France with 511 trials, and Germany with 504 trials.

Data Source

Number of clinical trials | ClinicalTrials.gov via Our World in Data

Data produced by ClinicalTrials.gov, compiled and published by Our World in Data as "Number of clinical trials".

Visit Data Source

Cite this page

Geo Factbook. (n.d.). Number of Clinical Trials by Country, 2012. Retrieved November 16, 2026, from https://geofactbook.com/fact/number-of-clinical-trials/2012

The figures on this page come from Number of clinical trials | ClinicalTrials.gov via Our World in Data. For academic work, cite the original source as well.

โ€บEmbed this ranking on your site

Free to embed with attribution. Shows the top 10 countries and links back to the full ranking.

Preview

Historical Data by Year

Explore Number of Clinical Trials data across different years. Compare trends and see how statistics have changed over time.